Inactive Instrument

MURY CANYPAR

Equities

MURF

US6266421022

Murphy Canyon Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 10:15 pm

Murphy Canyon Acquisition Corp. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 0.343711 million compared to USD 0.117539 million a year ago.
For the six months, net loss was USD 0.223442 million compared to USD 0.371075 million a year ago.

Latest news about MURY CANYPAR

Murphy Canyon Acquisition Corp.(NasdaqGM:MURF) dropped from NASDAQ Composite Index	22/09/23	CI
Conduit Pharmaceuticals Limited completed the acquisition of Murphy Canyon Acquisition Corp. from Murphy Canyon Acquisition Sponsor, LLC and others in a reverse merger agreement.	21/09/23	CI
Sector Update: Financial Stocks Sliding Late Thursday Afternoon	21/09/23	MT
Sector Update: Financial Stocks Lower in Afternoon Trading	21/09/23	MT
Top Midday Gainers	21/09/23	MT
Rate Hike Fears Weigh on Sentiment, Driving Premarket Losses for US Equity Futures	21/09/23	MT
Top Premarket Gainers	21/09/23	MT
Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc and Conduit Pharmaceuticals Limited Approve Board Elections	21/09/23	CI
Murphy Canyon Acquisition Corp. has Changed its Name to Conduit Pharmaceuticals Inc	21/09/23	CI
Murphy Canyon Acquisition Shareholders OK Pending Merger with Conduit Pharmaceuticals	21/09/23	MT
Murphy Canyon Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Murphy Canyon Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Murphy Canyon Acquisition Corp. Auditor Raises 'Going Concern' Doubt	27/03/23	CI
Conduit Pharmaceuticals Limited entered into a definitive Business Combination Agreement to acquire Murphy Canyon Acquisition Corp. from Murphy Canyon Acquisition Sponsor, LLC and others for approximately $660 million in a reverse merger agreement.	07/11/22	CI
Murphy Canyon Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	07/11/22	CI
Certain Class B Common Stock of Murphy Canyon Acquisition Corp. are subject to a Lock-Up Agreement Ending on 1-AUG-2022.	31/07/22	CI
Murphy Canyon Acquisition Corp.(NasdaqGM:MURF) added to NASDAQ Composite Index	29/03/22	CI
Murphy Canyon Acquisition Corp. announced that it has received $7.54 million in funding from Murphy Canyon Acquisition Sponsor, LLC	06/02/22	CI
Murphy Canyon Acquisition Corp. has completed an IPO in the amount of $115 million.	02/02/22	CI
Murphy Canyon Acquisition Corp. announced that it expects to receive $6.85 million in funding from Murphy Canyon Acquisition Sponsor, LLC	01/02/22	CI
Murphy Canyon Acquisition Corp. has filed an IPO in the amount of $150 million.	06/01/22	CI

Chart MURY CANYPAR

Duration

Period

More charts

Company Profile

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Companyâs licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimotoâs Thyroiditis. The Companyâs asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimotoâs Thyroiditis (HT) and Gravesâ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimotoâs Thyroiditis and Gravesâ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).

Sector

More about the company